Opens in a new tab

NRx Pharmaceuticals (Nasdaq: NRXP)

Published on March 5, 2024 | By admin

Major FDA Victory! Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus

A Landmark October 30 FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) at an Important Turning Point in Its Growth Strategy

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) $NRXP has announced a major regulatory achievement that could mark a defining moment in the company’s development. On October 30, 2026, NRx announced that the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine, delivering the approval ahead of the agency’s previously announced November 10 goal date. This is an important achievement for a company that has spent considerable time advancing its formulation, manufacturing capabilities, regulatory submissions, and commercial preparations. With FDA approval now secured and commercial manufacturing supply already on hand, NRx is positioned to move toward supplying American hospitals and clinics with its preservative-free ketamine product. The announcement also brings together several developments achieved during the past six months, including manufacturing process validation, encouraging two-year stability results, an approximately $11.25 million DARPA contract, advanced robotic brain stimulation initiatives, and continued development of its broader pharmaceutical pipeline. For investors following the neuroscience and mental health sector, this is an especially significant development in the NRx story.

FDA Approval Arrives Ahead of Schedule: A Major Milestone for NRXP

The October 30 announcement is the headline achievement. The FDA has approved NRx’s ANDA for preservative-free ketamine ahead of its November 10 GDUFA goal date. This approval clears an important regulatory hurdle for the company’s commercial ketamine product and allows NRx to move forward with product labeling and preparations to supply healthcare providers.

One of the distinguishing characteristics of the company’s formulation is the absence of benzethonium chloride (BZT), an antimicrobial preservative found in existing ketamine injection products discussed in the company’s announcement. NRx has focused on developing a sterile, preservative-free presentation that maintains product purity, potency, and sterility without relying on this ingredient.

The company believes this offers an important opportunity for hospitals and clinics, particularly given the ongoing challenges surrounding the supply of sterile injectable medicines. Ketamine injection has experienced supply shortages, and NRx has emphasized the importance of establishing dependable domestic manufacturing capacity.

CEO Jonathan Javitt, MD, MPH, highlighted the opportunity to bring the product to market and provide physicians and patients with another option for repeat treatments without the preservative-related concerns identified by the company.

The approval also represents an important achievement for American pharmaceutical manufacturing. NRx worked with Nephron Pharmaceuticals in West Columbia, South Carolina, to establish domestic production using modern blow-fill-seal manufacturing technology. The company believes this approach demonstrates the potential to bring additional sterile injectable pharmaceutical manufacturing back to the United States.

Commercial Manufacturing Is Already Prepared

One of the most encouraging developments leading into the FDA decision was NRx’s October 19 announcement confirming completion of three commercial process validation lots of preservative-free ketamine.

The company reported that all three lots were manufactured under commercial conditions in compliance with the process validation requirements of FDA Good Manufacturing Practices. This represented an important manufacturing milestone ahead of the anticipated regulatory decision.

NRx also announced completion of two-year, real-time room-temperature stability testing. According to the company, the results demonstrated no deterioration in purity, potency, or sterility without the need for preservatives.

The company believes these results are consistent with a potential labeled shelf life of three years or longer, subject to applicable regulatory requirements.

Importantly, NRx reported that commercially releasable drug supply was already on hand pending ANDA approval. With the October 30 approval now announced, the company has moved beyond the regulatory uncertainty that surrounded its immediate ketamine commercialization opportunity.

The combination of FDA approval, completed manufacturing validation, and available commercial supply gives NRx an important foundation as it moves toward commercialization.

An $11.25 Million DARPA Contract Creates Another Major Opportunity

While the FDA approval is understandably receiving significant attention, NRx has another important development that could contribute to its longer-term growth.

On September 30, NRx Defense Systems announced an approximately $11.18 million prime contract from the Defense Advanced Research Projects Agency (DARPA). The October 30 corporate announcement subsequently referenced an approximately $11.25 million contract to conduct a Phase 3 trial evaluating NRX-101 in combination with robotic neuronavigated transcranial magnetic stimulation.

The SPARC-TMS program is designed to investigate a single-day treatment approach for patients with treatment-resistant depression.

The initiative brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.

This is an important development because it combines an investigational pharmaceutical candidate with advanced brain stimulation technology and a government-funded clinical research program.

The contract has an 18-month performance period, with funding tied to program milestones and additional funding subject to applicable appropriations and contract options.

If successful, the research could provide an additional development pathway for NRX-101 and potentially support further opportunities in the treatment of difficult-to-treat depression.

HOPE Therapeutics and Robotic TMS Expand the Company’s Reach

NRx’s HOPE Therapeutics subsidiary is another important part of the company’s broader strategy.

In September, NRx announced preparations to deploy Zeta Surgical’s FDA-cleared robotic TMS navigation system at HOPE’s Florida clinics.

The technology is designed to assist clinicians with precise TMS positioning through advanced navigation software. This complements NRx’s interest in combining pharmaceutical development with technology-enabled psychiatric treatment.

The relationship between HOPE Therapeutics, robotic TMS, and the SPARC-TMS clinical research program gives NRx an opportunity to connect its pharmaceutical pipeline with an expanding interventional psychiatry platform.

Rather than relying on a single product opportunity, the company is developing several interconnected initiatives in mental health treatment and neurological research.

NRX-100 and NRX-101: A Broader Pharmaceutical Pipeline

NRx’s development strategy includes two important pharmaceutical programs.

NRX-100 is preservative-free intravenous ketamine. The newly announced ANDA approval represents a major achievement for its commercial product pathway. Separately, the company is pursuing an NDA for potential treatment claims involving depression and suicidal ideation, including bipolar depression. NRX-100 has received FDA Fast Track Designation for this development program.

NRX-101 is an investigational oral combination of D-cycloserine and lurasidone. The company is developing it for serious depression-related conditions, including suicidal bipolar depression, and has reported FDA Breakthrough Therapy Designation for this program.

These are separate development opportunities with different regulatory requirements. The October 30 ANDA approval does not constitute approval of the separate NRX-100 NDA or NRX-101.

Nevertheless, the combination of an approved commercial ketamine product and additional investigational programs gives NRx multiple opportunities to pursue its broader mission in neuroscience and mental health.

Financial Preparation and the Next Stage of Growth

In its August 17 second-quarter 2026 corporate update, NRx reported approximately $26.7 million in cash and cash equivalents as of June 30, 2026, and approximately $22.3 million in gross proceeds from an underwritten public offering.

The company also described its commercial preparation efforts, including manufacturing plans and launch inventory development.

Now that the preservative-free ketamine ANDA has received FDA approval, investors will be watching for further information about commercial distribution, customer relationships, initial orders, revenue generation, and the financial resources required to support expansion.

The approval represents an important regulatory achievement, while actual commercial performance will depend on execution, market adoption, manufacturing, distribution, and reimbursement considerations.

The Bottom Line: A Landmark Day for NRx Pharmaceuticals

October 30, 2026, will stand out as an important date in the NRx Pharmaceuticals story. FDA approval of preservative-free ketamine ahead of the November 10 goal date represents a major accomplishment following months of regulatory work, manufacturing preparation, and stability testing.

The company now has an approved ANDA for its preservative-free ketamine product, completed commercial process validation, two-year stability results, and manufactured commercial supply. These achievements provide an important foundation for its next phase of development.

Beyond ketamine, the approximately $11.25 million DARPA research contract, SPARC-TMS initiative, HOPE Therapeutics platform, and NRX-101 development program offer additional opportunities to watch.

For investors, the focus now shifts toward commercialization and the company’s ability to translate its regulatory and research achievements into sustainable business growth.

NRx Pharmaceuticals has reached a significant milestone, and its next chapter will be defined by execution. With FDA approval now secured for preservative-free ketamine, the company has an important opportunity to establish its position in the sterile injectable pharmaceutical market while continuing to pursue its broader ambitions in neuroscience and mental health.

FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRXP Also Received $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression

WILMINGTON, Del., October 30, 2026 —

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) $NRXP, a commercial biopharmaceutical company developing medicines that target depression, PTSD, and suicidality has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced November 10, approval Goal Date.

“We are excited to bring Preservative-Free Ketamine to market and give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in some formulations by the US Food and Drug Administration,” said Jonathan Javitt, MD, MPH, NRXP Chairman and Chief Executive Officer.

Currently available ketamine injection products all contain benzethonium chloride (BZT). According to current regulation, inactive ingredients in drugs (including preservatives) must be Generally Recognized As Safe (“GRAS”) or proven to be safe. The FDA has declined to designate Benzethonium Chloride as GRAS. Under current FDA policy, benzethonium chloride cannot be included in new drugs, consumer hand cleansers, wipes, healthcare or surgical hand rubs nor in intravenous formulations above a threshold concentration for toxicological reasons. Ketamine is one of the few remaining old drugs, initially formulated in 1970 to contain BZT. Prior to the NRXP novel formulation, it was widely believed that BZT was required for long-term stability and sterility of ketamine.

NRXP has filed a Citizen Petition with FDA seeking to have BZT removed from ketamine and an expert Toxicology report is available to the public on the FDA docket. That report, compiled by a Board Certified Toxicologist under the supervision of a leading Regulatory Law Firm, documents that at dosages of ketamine that are routinely used in hospitals and clinics for labeled indications, patients may be exposed to levels of BZT that exceed the published toxicity thresholds.

Federal policymakers have addressed the threat to the United States of a sterile injectable drug supply that is largely manufactured offshore. Traditional, labor-intensive, glass bottle manufacturing of these drugs has not been economically viable in the United States for decades. The NRXP presentation of Ketamine demonstrates that manufacture of old-line sterile, injectable drugs can be reshored to the United States for the benefit of American patients, workers, and investors.

The approval of Ketamine ahead of its Generic Drug User Fee Act (GDUFA) goal date by the FDA Office of Generic Drugs demonstrates FDA’s commitment to timely and efficient approval of drug-shortage drugs.

Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

NRXP has announced completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Act) Goal Date. Process Validation is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).

NRXP has also completed analysis of two-year room temperature real-time stability data on preservative-free ketamine demonstrating no deterioration in purity, potency, or sterility without the need for toxic preservatives. NRXP believes that these data will be consistent with a labeled shelf life of three years or longer.

$11 Million Dollar DARPA Prime Contract Award to Evaluate Robotic Magnetic Stimulation in Conjunction with NRX-101 for Treatment of Resistant Depression

NRXP subsidiary NRx Defense Systems has announced the award of an initial $11,177,757.27 contract issued by the Defense Advanced Research Projects Agency, a Branch of the United States Department of War. The underlying clinical trial, the Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) trial has been approved by the US Food and Drug Administration and will now begin enrolling patients.

The NRXP SPARC-TMS trial will be conducted at Harvard Medical School’s McLean Hospital, Arizona State University, and HOPE Therapeutics. Several leading military hospitals will also be affiliated with the study.

The focus of SPARC-TMS is to test whether an entire course of TMS delivered in a single day can effectively treat major depressive disorder when combined with mechanism-guided pharmacologic augmentation with NRXP NRX-101. TMS is thought to exert its therapeutic effects primarily through synaptic plasticity – the cellular basis of learning and memory. Synaptic plasticity is mediated by NMDA receptors. NRX-101 combines two drugs that may enhance NMDA receptor function through complementary mechanisms: d-cycloserine, an NMDA receptor partial agonist, and lurasidone, which has been shown to increase NMDA receptor expression through 5-HT7 antagonism.

The SPARC-TMS trial has the potential to serve as an FDA registration study for the use of NRXP NRX-101 in conjunction with TMS for people with Treatment Resistant Depression. a far larger population of patients, estimated at 8.9 million American adults with an estimated $44 Billion burden of illness.

European Patent Rights for GNK-301, a Novel Drug Candidate to Treat Amyotrophic Lateral Sclerosis (ALS)

GeNeuro, Inc., a subsidiary of NRXP has announced the award of a European Patent (EP 3 570 878 B1) entitled “Anti HERV K Envelope Antibody and Uses Thereof.” The patent, together with two previously-issued US patents (10,723,787 and 10,981,977) describes in detail the discovery that the envelope protein (K Env) of Human Endogenous Retrovirus K (HERV K) is found in the spinal fluid of more than 75% of people with Amyotrophic Lateral Sclerosis (ALS), is shown to be highly neurotoxic, and to produce the neurodegenerative findings of ALS.

HERVs are the remnants of viruses that infected primates between 2 and 5 million years ago and are now thought to have played a role in human disease. A monoclonal antibody against K Env (GNK-301) has been shown to block those neurotoxic effects in the same models. The patents are jointly owned by GeNeuro and the US Dept. of Health and Human Services.

The assets of the former Geneuro SA were awarded to NRXP GeNeuro, Inc. by the Courts of Switzerland in June 2026 and GeNeuro initiated manufacture of GNK-301 under Good Manufacturing Practices (cGMP) with the plan to initiate human Phase 1 trials of GNK-301 in the US and Europe in the latter half of 2027.

FDA Approval of Preservative-Free Ketamine Received Ahead of November 10th FDA Goal Date.
Ketamine, Originally Formulated in 1970 is One of the Last Remaining Sterile Drugs to Contain the Preservative Benzethonium Chloride.
Plan to Return sterile, Injectable Drug Manufacture to the US and end the Current Shortage of Traditional Glass-Bottled Ketamine via Modern, High-Volume Means.
Approval Demonstrates Sterile, Injectable Drug Manufacturing can be Reshored to the US from Overseas Sources of Supply Using Modern Technology.
Three Commercial Lots of Preservative-Free Ketamine Manufactured in Compliance with “Process Validation” Required Under FDA “Good Manufacturing Practices” (GMP).
Two Year Stability Data Consistent with Projected Room-Temperature Stability to Three Years and Beyond with No Need for Toxic Preservatives.
$11 Million Dollar DARPA Prime Contract Award to Evaluate Robotic Magnetic Stimulation with NRX-101 Drug for Treatment of Resistant Depression,
Plans Underway to Expand SPARC-TMS Trial to Leading Military Hospitals.
Subsidiary GeNeuro, Inc., Awarded European Patent Rights for GNK-301, a Novel Drug Candidate to Treat Amyotrophic Lateral Sclerosis (ALS).
Worldwide Generic Ketamine Market Estimated at $750 Million Per Year.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious central nervous system (CNS) disorders, with particular emphasis on suicidal depression, suicidal bipolar depression, PTSD and chronic pain. The company is developing therapies designed to address significant unmet medical needs, while also building HOPE Therapeutics, a clinical-care platform focused on advanced interventional psychiatric treatment.

Mission

NRx’s mission is “to bring hope” through life-saving medicines for people living with unmet medical needs. The company says it seeks to use breakthrough science to make diseases that are difficult or previously untreatable more manageable, with a particular focus on bringing innovative treatments to patients with serious and life-threatening conditions.

NRx Pharmaceuticals, Inc. was legally incorporated in Delaware on September 18, 2017.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

COMPANY NEWS:

Company Name: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Contact: Brian Korb, Managing Partner, astr partners
Email: brian.korb@astrpartners.com
Phone: +19176535122
Country:United States 
Website: https://www.nrxpharma.com/
Other websites: https://axecapitalusa.com/nrxp/

Share this: